Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888066 · ClinicalTrials.gov registry record · Phase 3
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
A Phase 3 study, sponsored by Vifor Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,195
- Enrollment target
NCT03888066 is a Phase 3 study that has completed, run by Vifor Pharma. The registered enrollment target is 1,195 participants.
The verdict
NCT03888066, a Phase 3 study, has completed, sponsored by Vifor Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,195 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
Interventions
- DRUG Placebos
- DRUG Patiromer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,195 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03888066
The ClinicalTrials.gov registry entry for NCT03888066 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vifor Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03888066 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03888066 about?
NCT03888066 is a clinical study titled "Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)". The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
What is the current status of trial NCT03888066?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,195 participants. The study started on 2019-04-24. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT03888066?
The interventions under investigation include: Placebos (DRUG), Patiromer (DRUG).
Who is sponsoring clinical trial NCT03888066?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.